

# Erratum In: “Balancing Consideration of the Risks and Benefits of E-Cigarettes”

In: Balfour DJK, Benowitz NL, Colby SM, et al. Balancing consideration of the risks and benefits of e-cigarettes. *Am J Public Health*. 2021;111(9):1661–1672. <https://doi.org/10.2105/AJPH.2021.306416>

A conflict of interest was not properly disclosed. On page 1668, the Conflicts of Interest section should read: **AJPH**

## CONFLICTS OF INTEREST

N. L. Benowitz is a consultant to Pfizer and Achieve Life Sciences, companies that market or are developing smoking cessation medications, and has been an expert witness in litigation against tobacco companies. S. J. Leischow is conducting a clinical trial supported by Achieve Life Sciences, which is developing a nonnicotine medication for smoking cessation, and has consulted with them. He also consulted more than 1 year ago for GSK, which is working to bring a new nicotine-replacement product to market, and he receives medication for a National Institutes of Health–funded smoking-cessation study from Pfizer. N. A. Rigotti receives royalties from UpToDate Inc for writing about smoking cessation and e-cigarettes and is a consultant for Achieve Life Sciences for an investigational smoking-cessation medication. R. West has undertaken research and consultancy for Pfizer and GSK, companies that manufacture smoking-cessation medications. R. Niaura reviewed grant proposals from 2018–2019 for the Foundation for a Smokefree World, which was created by and remains fully funded by Philip Morris. R. Niaura did not receive any compensation for this activity, monetary or otherwise.

This addition does not affect the paper’s conclusions.

<https://doi.org/10.2105/AJPH.2021.306416>